Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXIX. Elevation of erythrocyte sedimentation rate is associated with disease activity and damage accrual

Journal of Rheumatology

Volumn 32, Issue 11, 2005, Pages 2150-2155

  Vilá, Luis M ^a,b,f   Alarcón, Graciela S ^c   McGwin Jr , Gerald ^d   Bastian, Holly M ^a   Fessler, Barri J ^c   Reveille, John D ^e  

^a Department of Medicine ^*  (Puerto Rico)

^b UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^c The University of Alabama at Birmingham   (United States)

^d Kentucky   (United States)

^e UNIVERSITY OF TEXAS   (United States)

^f UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

Clinical outcome; Disease activity; Disease damage; Erythrocyte sedimentation rate; Systemic lupus erythematosus

Indexed keywords

DNA ANTIBODY; DOUBLE STRANDED DNA;

ADULT; AFRICAN AMERICAN; ARTHRITIS; ARTICLE; CAUCASIAN; CLINICAL FEATURE; COHORT ANALYSIS; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; ETHNIC GROUP; FEMALE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; PHOTOSENSITIVITY; PRIORITY JOURNAL; RASH; REGRESSION ANALYSIS; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AFRICAN AMERICANS; ALABAMA; BLOOD SEDIMENTATION; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PSYCHOLOGY; PUERTO RICO; SEVERITY OF ILLNESS INDEX; TEXAS;

EID: 27744548883     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Zlonis M. The mystique of the erythrocyte sedimentation rate. A reappraisal of one of the oldest laboratory tests still in use. Clin Lab Med 1993;13:787-800.
2. Thomas RD, Westengard JC, Hay KL, Bull BS. Calibration and validation for erythrocyte sedimentation tests. Role of the International Committee on Standardization in Hematology. Arch Pathol Lab Med 1993;117:719-23.
3. Paulus HE, Ramos B, Wong WK, et al. Equivalence of the acute phase reactants C-reactive protein, plasma viscosity, and Westergren erythrocyte sedimentation rate when used to calculate American College of Rheumatology 20% improvement criteria or the Disease Activity Score in patients with early rheumatoid arthritis. Western Consortium of Practicing Rheumatologists. J Rheumatol 1999;26:2324-31.
4. Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990;33:1122-8.
5. Cantini F, Salvarani C, Olivieri I, et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum 2000;30:17-24.
6. Pistiner M, Wallace DJ, Nessin S, Metzger AL, Klinenberg JR. Lupus erythematosus in the 1980s: a survey of 570 patients. Semin Arthritis Rheum 1991;21:55-64.
7. Donald F, Ward MM. Evaluative laboratory testing practices of United States rheumatologists. Arthritis Rheum 1998;41:725-9.
8. Samsonov MY, Tilz GP, Egorova O, et al. Serum soluble markers of immune activation and disease activity in systemic lupus erythematosus. Lupus 1995;4:29-32.
9. Chiu YY, Nisihara RM, Wurzner R, Kirschfink M, de Messias-Reason I. SC5b-9 is the most sensitive marker in assessing disease activity in Brazilian SLE patients. J Investig Allergol Clin Immunol 1998;8:239-44.
10. Boehme MW, Raeth U, Galle PR, Stremmel W, Scherbaum WA. Serum thrombomodulin-a reliable marker of disease activity in systemic lupus erythematosus (SLE): advantage over established serological parameters to indicate disease activity. Clin Exp Immunol 2000;119:189-95.
11. Taysi S, Gul M, Sari RA, Akcay F, Bakan N. Serum oxidant/antioxidant status of patients with systemic lupus erythematosus. Clin Chem Lab Med 2002;40:684-8.
12. Reveille JD, Moulds JM, Ahn C, et al. Systemic lupus erythematosus in three ethnic groups: I. The effects of HLA-Class II, C4 and CR1 alleles, socioeconomic factors and ethnicity at disease onset. Arthritis Rheum 1998;41:1161-72.
13. Alarcon GS, Roseman J, Bartolucci AA, et al. Systemic lupus erythematosus in three ethnic groups: II. Features predictive of disease activity early in its course. Arthritis Rheum 1998;41:1173-80.
14. Vila LM, Alarcón GS, McGwin G Jr, et al. Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations. Rheumatology Oxford 2004;43:358-63.
15. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
16. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107-18.
17. Liang MH, Fortin PR, Isenberg DA, Snaith L. Quantitative clinical assessment of disease activity in systemic lupus erythematosus: progress report and research agenda. Rheumatol Int 1991;11:133-6.
18. Stoll T, Stucki G, Malik J, Pyke S, Isenberg DA. Association of the Systemic Lupus Erythematosus International Collaborating Clinics/American College of Rheumatology Damage Index with measures of disease activity and health status in patients with systemic lupus erythematosus. J Rheumatol 1997;24:309-13.
19. Mirzayan MJ, Schmidt RE, Witte T. Prognostic parameters for flare in systemic lupus erythematosus. Rheumatology Oxford 2000;39:1316-9.
20. Chang ER, Abrahamowicz M, Ferland D, Fortin PR. Organ manifestations influence differently the responsiveness of 2 lupus disease activity measures according to patients' or physicians' evaluations of recent lupus activity. J Rheumatol 2002;29:2350-8.
21. Witte T, Hartung K, Matthias T, et al. Association of IgA anti-dsDNA antibodies with vasculitis and disease activity in systemic lupus erythematosus. SLE Study Group. Rheumatol Int 1998;18:63-9.
22. Studnicka-Benke A, Steiner G, Petera P, Smolen JS. Tumor necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 1996;35:1067-74.
23. Sfikakis PP, Charalambopoulos D, Vayiopoulos G, Oglesby R, Sfikakis P, Tsokos GC. Increased levels of intercellular adhesion molecule-1 in the serum of patients with systemic lupus erythematosus. Clin Exp Rheumatol 1994;12:5-9.
24. Zhang Y, Geng H, Zhao M, et al. The significance of anti-endothelial cell antibodies in patients with lupus nephritis and immunoblotting analysis of the target components. Chin Med J Engl 1999;112:597-602.
25. Witte T, Hartung K, Sachse C, et al. Rheumatoid factors in systemic lupus erythematosus: association with clinical and laboratory parameters. SLE Study Group. Rheumatol Int 2000;19:107-11.
26. Alarcon GS, McGwin G Jr, Bartolucci AA, et al. Systemic lupus erythematosus in 3 ethnic groups. IX. Differences in damage accrual. Arthritis Rheum 2001;44:2797-806.
27. Ames PR, Alves J, Pap AF, Ramos P, Khamashta MA, Hughes GR. Fibrinogen in systemic lupus erythematosus: more than an acute phase reactant? J Rheumatol 2000;27:1190-5.
28. Estes D, Christian CL. The natural history of systemic lupus erythematosus by prospective analysis. Medicine 1971;50:85-95.
29. Schechner V, Shapira I, Berliner S, et al. Significant dominance of fibrinogen over immunoglobulins, C-reactive protein, cholesterol and triglycerides in maintaining increased red blood cell adhesiveness/aggregation in the peripheral venous blood: a model in hypercholesterolaemic patients. Eur J Clin Invest 2003;33:955-61.
30. Suzuki Y, Tateishi N, Cicha I, Maeda N. Aggregation and sedimentation of mixtures of erythrocytes with different properties. Clin Hemorheol Microcirc 2001;25:105-17.
31. Fincher RM, Page MI. Clinical significance of extreme elevation of erythrocyte sedimentation rate. Arch Intern Med 1986;146:1581-3.
32. Bathon J, Graves J, Jens P, Hamrick R, Mayes M. The erythrocyte sedimentation rate in end-stage renal failure. Am J Kidney Dis 1987;10:34-40.
33. Monig H, Marquardt D, Arendt T, Kloehn S. Limited value of elevated erythrocyte sedimentation rate as an indicator of malignancy. Fam Pract 2002;19:436-8.
34. van den Broe NR, Letsky EA. Pregnancy and the erythrocyte sedimentation rate. BJOG 2001;108:1164-7.